{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:26:57Z","timestamp":1790980017422,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>High-dose methotrexate is used for treating several types of cancer. However, it is associated with a high risk of acute kidney injury (AKI), especially in patients with high MTX concentrations. Although therapeutic drug monitoring is performed to monitor MTX concentrations, it is unclear what concentration should be considered critical, thus requiring rescue protocols to prevent nephrotoxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Patients treated with high-dose methotrexate for lymphoma or acute lymphoblastic leukemia and those benefited from therapeutic drug monitoring were included. The relationship between MTX concentrations and the presence or absence of AKI was assessed. MTX concentrations were analyzed using a population pharmacokinetic approach. Specific attention was given to morphological covariates because MTX doses are individualized according to body surface area (BSA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In total, 328 patients and 657 cycles of treatment were analyzed. Higher MTX concentrations were observed in the AKI+ group. For cycle 1, all patients showing an MTX concentration &gt;6 \u00b5M at 36 hours or &gt;2 \u00b5M at 48 hours after infusion developed nephrotoxicity. The final pharmacokinetic model had 2 compartments and included the effect of age on clearance (CL) and of body weight on peripheral distribution volume. None of the morphological covariates tested on CL led to significant improvement in the model. Higher MTX concentrations were observed in patients with extreme BSA values (\u22652 m<jats:sup>2<\/jats:sup>) or body mass index (\u226525 kg\/m<jats:sup>2<\/jats:sup>). Patients with AKI who received at least 1 cycle had higher BSA and BMI.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The results from this study provide additional information on the relationship between MTX concentration and nephrotoxicity. Patients with a plasma MTX concentration &gt;6 \u00b5M at 36 hours were more likely to manifest AKI. In addition, the results suggest that overweight patients have a high AKI risk and that BSA-based adjustment of MTX dose is not appropriate.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000813","type":"journal-article","created":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T09:00:29Z","timestamp":1599987629000},"page":"408-415","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Body Surface Area Dosing of High-Dose Methotrexate Should Be Reconsidered, Particularly in Overweight, Adult Patients"],"prefix":"10.1097","volume":"43","author":[{"given":"Fanny","family":"Gallais","sequence":"first","affiliation":[{"name":"Centre de Recherches en Canc\u00e9rologie de Toulouse, INSERM UMR-1037, CNRS ERL5294, Universit\u00e9 Paul Sabatier;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Oberic","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie, Institut Universitaire du Cancer de Toulouse-Oncopole;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Faguer","sequence":"additional","affiliation":[{"name":"D\u00e9partement de N\u00e9phrologie et Transplantation d'organes, Centre de r\u00e9f\u00e9rence des maladies r\u00e9nales rares, H\u00f4pital Rangueil, Centre Hospitalier Universitaire de Toulouse;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Tavitian","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie, Institut Universitaire du Cancer de Toulouse-Oncopole;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lafont","sequence":"additional","affiliation":[{"name":"Centre de Recherches en Canc\u00e9rologie de Toulouse, INSERM UMR-1037, CNRS ERL5294, Universit\u00e9 Paul Sabatier;"},{"name":"Laboratoire de pharmacologie, Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Marsili","sequence":"additional","affiliation":[{"name":"Laboratoire de pharmacologie, Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Brice","sequence":"additional","affiliation":[{"name":"Laboratoire de pharmacologie, Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Chatelut","sequence":"additional","affiliation":[{"name":"Centre de Recherches en Canc\u00e9rologie de Toulouse, INSERM UMR-1037, CNRS ERL5294, Universit\u00e9 Paul Sabatier;"},{"name":"Laboratoire de pharmacologie, Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Puisset","sequence":"additional","affiliation":[{"name":"Centre de Recherches en Canc\u00e9rologie de Toulouse, INSERM UMR-1037, CNRS ERL5294, Universit\u00e9 Paul Sabatier;"},{"name":"Laboratoire de pharmacologie, Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole; and"},{"name":"D\u00e9partement Pharmacie, Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","first-page":"6228","article-title":"Progress in the chemotherapeutic treatment of osteosarcoma","volume":"16","author":"Zhang","year":"2018","journal-title":"Oncol Lett."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/annonc\/mdi075","article-title":"High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma","volume":"16","author":"Jahnke","year":"2005","journal-title":"Ann Oncol."},{"issue":"suppl 5","key":"R3-20250603","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Hoelzer","year":"2016","journal-title":"Ann Oncol."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/leu.2017.283","article-title":"High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG","volume":"32","author":"Sakura","year":"2018","journal-title":"Leukemia."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1158\/1078-0432.CCR-04-0159","article-title":"Treatment of relapsed central nervous system lymphoma with high-dose methotrexate","volume":"10","author":"Plotkin","year":"2004","journal-title":"Clin Cancer Res."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1215\/15228517-2008-067","article-title":"High-dose methotrexate for elderly patients with primary CNS lymphoma","volume":"11","author":"Zhu","year":"2009","journal-title":"Neuro Oncol."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/asheducation-2006.1.311","article-title":"An update on therapy of primary central nervous system lymphoma","volume":"2006","author":"DeAngelis","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Widemann","year":"2006","journal-title":"Oncologist."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.ejca.2014.04.014","article-title":"Review of therapeutic drug monitoring of anticancer drugs part 1\u2014Cytotoxics","volume":"50","author":"Paci","year":"2014","journal-title":"Eur J Cancer."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1634\/theoncologist.12-11-1299","article-title":"Glucarpidase (carboxypeptidase G2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy","volume":"12","author":"Schwartz","year":"2007","journal-title":"Oncologist."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","article-title":"Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance","volume":"23","author":"Ramsey","year":"2018","journal-title":"Oncologist."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1200\/JCO.2007.13.1078","article-title":"Obesity in dose calculation: a mouse or an elephant?","volume":"25","author":"Gurney","year":"2007","journal-title":"J Clin Oncol."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.2011.39.9436","article-title":"Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline","volume":"30","author":"Griggs","year":"2012","journal-title":"J Clin Oncol."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbmt.2014.01.019","article-title":"Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee","volume":"20","author":"Bubalo","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.bbmt.2018.11.005","article-title":"Effect of conditioning regimen dose reduction in obese patients undergoing autologous hematopoietic cell transplantation","volume":"25","author":"Brunstein","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s00280-006-0202-0","article-title":"Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy","volume":"58","author":"Faltaos","year":"2006","journal-title":"Cancer Chemother Pharmacol."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3109\/10428194.2013.840780","article-title":"High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis","volume":"55","author":"May","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hon.2479","article-title":"Delayed methotrexate elimination: incidence, interaction with antacid drugs, and clinical consequences?","volume":"36","author":"Ranchon","year":"2018","journal-title":"Hematol Oncol."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2003.11.036","article-title":"Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group","volume":"21","author":"Hoang-Xuan","year":"2003","journal-title":"J Clin Oncol."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM197709222971203","article-title":"Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity","volume":"297","author":"Stoller","year":"1977","journal-title":"N Engl J Med."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00262416","article-title":"Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients","volume":"3","author":"Evans","year":"1979","journal-title":"Cancer Chemother Pharmacol."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.2215\/CJN.00710113","article-title":"World incidence of AKI: a meta-analysis","volume":"8","author":"Susantitaphong","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/bcp.12326","article-title":"Urinary coproporphyrin I\/(I\u2009+\u2009III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance","volume":"78","author":"Benz-de Bretagne","year":"2014","journal-title":"Br J Clin Pharmacol."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00280-013-2206-x","article-title":"Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments","volume":"72","author":"Pauley","year":"2013","journal-title":"Cancer Chemother Pharmacol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:23:22Z","timestamp":1748971402000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000813","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"2020-05-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}